Status:
COMPLETED
Special Survey of Production of Insulin Aspart Specific Antibody
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 1
Eligibility:
All Genders
Brief Summary
This study is conducted in Japan. The aim of this study is to collect data of production of insulin aspart specific antibody under normal clinical practice conditions.
Eligibility Criteria
Inclusion
- Patients with diabetes requiring insulin therapy
Exclusion
- Patients who had a treatment history of NovoRapid® (insulin aspart)
Key Trial Info
Start Date :
April 1 2002
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2009
Estimated Enrollment :
204 Patients enrolled
Trial Details
Trial ID
NCT01487369
Start Date
April 1 2002
End Date
October 1 2009
Last Update
March 4 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tokyo, Japan, 1000005